The combination of pembrolizumab and docetaxel significantly improved ORR and PFS in patients with advanced NSCLC and previous progression after platinum-based chemotherapy, with or without EGFR variations (22). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.